The director of the ISCIII, Marina Pollán, and the president of Farmaindustria, Fina Lladós, have signed a General Action Protocol to promote research, innovation and knowledge transfer in the field of health in Spain.

Farmaindustria.es

The Carlos III Institute of Health (ISCIII) and Farmaindustria have signed a General Action Protocol (PGA) that establishes the basis for collaboration between both entities, with the aim of promoting research, innovation and knowledge transfer in the field of health in Spain.

To present and launch this collaboration, the director of the ISCIII, Marina Pollán, and the president of Farmaindustria, Fina Lladós, held a working meeting this Tuesday at the Institute with part of their management teams.

The agreement aims to strengthen the prevention, diagnosis and treatment of diseases through joint scientific, educational and dissemination initiatives. It also lays the foundations for the creation of strategic alliances and new forms of public-private cooperation.

The EMP contemplates a series of priority lines for the development of future projects, among which the following stand out:

• The promotion of preclinical and translational research and technology transfer.
• Promoting innovation in health and the Spanish biomedical ecosystem throughout the life cycle of the medicine.
• Consolidation of Spain’s leadership in clinical research, including training and support for structures promoted by the ISCIII.
• Collaboration in advanced therapies and personalised medicine, with a sustainable and territorially structured vision.
• The promotion of international and European public-private research initiatives.
• Promoting the rational use of medicines through clinical and real-life studies.
• Scientific dissemination to bring advances in health closer to the public.

Farmaindustria.es

ISCIII Director Marina Pollán says: “We at the ISCIII are very pleased to forge a new framework for cooperation that will help us to continue promoting biomedical research. Moving forward together, enhancing public-private collaboration, is a logical consequence of the ties we already have and will allow us to open new avenues of work in the field of clinical research, precision medicine and health care”.

The president of Farmaindustria, Fina Lladós Canela, says: “At Farmaindustria, we are convinced that this agreement will allow Spain to continue advancing in biomedical R&D, whose objective is none other than improving the health of patients and the well-being of society. With this new framework for action we will be able to intensify work in important areas such as preclinical and translational research and consolidate our leadership in clinical research, all under the public-private collaboration model, which has proven to be the most successful for health, economic and social development.